Clinical Trial Update: A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of romiplostim (AMG 531) in patients with myelodysplastic syndromes receiving Revlimid. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)
• Revlimid (lenalidomide)

Snippet

Sponsor: Amgen | Conditions: Myelodysplastic Syndromes, Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2010-12-22